(Q46845168)

English

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Millot F

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Guilhot J

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Leblanc T

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

De Bont ES

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Békassy AN

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Gadner H

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Sufliarska S

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Stary J

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Gschaidmeier H

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Guilhot F

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 February 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

187-192

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341042%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404051

0 references

Stem cell transplantation for chronic myeloid leukemia in children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

21 January 2018

Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404051

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46845168&oldid=1584558333"